The Next Generation of Cellular Therapies

Our Company

A Novel Approach to Cancer Cell Therapy

We are a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for solid and hematological tumors. Our platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies designed to effectively identify and eradicate tumor cells. We are one of the most advanced gamma-delta T cell companies and were the first to bring genetically modified gamma-delta T cells into the clinic. We are utilizing our suite of DeltEx platform technologies to achieve our mission of what we refer to as CANCER ZERO ─ the elimination of all cancer cells in every patient battling the disease. We believe this aspiration will one day be achievable and that it is our responsibility to advance next-generation cancer treatments for patients in need.

Our lead product candidates are clinical stage assets. INB-400 is currently in a Phase 2 clinical trial for the treatment of newly diagnosed glioblastoma or GBM while the Phase 1, INB-200, also in newly diagnosed GBM is nearing completion. INB-100 is in a Phase 1 clinical trial for the treatment of patients with leukemia that are undergoing hematopoietic bone marrow transplantation. Our platform has also yielded a broad portfolio of preclinical and discovery-stage programs focused on addressing solid tumors.

Learn More About Our Pipeline

Our DeltEx Platform

Gamma-delta T cells are naturally occurring immune cells with unique properties enabling them to intrinsically differentiate between healthy and diseased tissue. They serve as a functional bridge between the innate and adaptive immune system, contributing to direct tumor cell killing as well as immune cell recruitment and activation to drive deeper immune responses. The pivotal role of gamma-delta T cells in immune function against diseases such as cancer underscores their therapeutic potential across a wide range of solid and hematologic malignancies. We develop ex vivo expanded and activated gamma-delta T cell therapeutic candidates based upon our deep expertise in gamma-delta T cell biology, proprietary genetic engineering and cell-type specific manufacturing capabilities, collectively known as our DeltEx platform.

Learn More About Our Technology

A Strategic Vision

We are dedicated to leveraging our DeltEx platform to develop next-generation cellular therapies that we believe can dramatically improve outcomes for cancer patients. We have assembled a team of experts in the discovery, development and manufacturing of gamma-delta T cell therapies. We are led by William Ho, our founder and Chief Executive Officer, who has over 22 years of experience in healthcare finance, investing and managing biotech companies. Our scientific founder and Chief Scientific Officer, Dr. Lawrence Lamb, is a pioneer in gamma-delta T cell biology and manufacturing, who published the foundational work identifying their potential antileukemic effect and their association with improved overall survival in cancer patients. Dr. Lamb and our team’s expertise has directed the development of our DeltEx platform and technology. The company is supported by our Scientific Advisory Board, which includes a globally renowned group of clinicians, oncologists and immunologists.

Learn More About Our Team